- Scott L. Friedman, M.D.
Dr. Friedman is the Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai. More »
Continuously funded by NIH since 1985, he has performed pioneering research into the underlying causes of fibrosis associated with chronic liver disease and was among the first to isolate and characterize the hepatic stellate cell, which is the primary fibrogenic cell in the liver. His honors include the International Hans Popper Award, a Senior Fulbright Fellowship at the Weizmann Institute, the EASL International Recognition Award, the AASLD and ALF Distinguished Achievement Awards, and dozens of visiting Professorships worldwide. He was elected as a Fellow of the American Gastroenterological Association in 2008, the American College of Physicians in 2013, the American Association for the Study of Liver Diseases in 2014, and the American Association for the Advancement for Science in 2015. He was previously a faculty member at the University of California, San Francisco, where he pursued his Gastroenterology Fellowship. Dr. Friedman completed his medical residency at the Beth Israel Hospital at Harvard Medical School and received his M.D. from the Icahn School of Medicine at Mount Sinai.« Less
- Neil Henderson, M.B.Ch.B, Ph.D.
Dr. Henderson is Chair of Tissue Repair & Regeneration, Wellcome Trust Senior Research Fellow in Clinical Science, and Honorary Consultant Hepatologist at the Centre for Inflammation Research of the University of Edinburgh Medical School. More »
His lab uses a variety of cutting-edge approaches, including intravital imaging and the rapidly evolving field of single-cell RNA sequencing. He has also been awarded a Wellcome Trust Senior Research Fellowship in Clinical Science to investigate novel mechanisms of organ fibrosis and regeneration. Dr. Henderson undertook medical training in Edinburgh and London before completing a Wellcome Trust-funded Ph.D. at the MRC Centre for Inflammation Research. He then trained in hepatology and was awarded a Wellcome Trust Intermediate Fellowship, during which time he pursued post-doctoral work at the University of California, San Francisco.« Less
- Toby M. Maher, M.B., M.Sc., Ph.D.
Dr. Maher currently serves as British Lung Foundation Chair in Respiratory Research and Professor of Interstitial Lung Disease at the National Heart and Lung Institute at Imperial College London, UK. More »
He also holds a prestigious National Institute of Health Research Clinician Scientist Fellowship and is Director of Respiratory Research and a consultant physician at Royal Brompton Hospital, London. His research interests include biomarker discovery, the lung microbiome, and host immune response in the pathogenesis of IPF, and he has been actively involved in the running of over 45 clinical trials in fibrotic lung disease. Dr. Maher is an associate editor for American Journal of Respiratory and Critical Care Medicine and serves on the editorial board of European Respiratory Journal and European Respiratory Review and on the International Advisory Board for Lancet Respiratory Medicine. He has authored over 200 papers and book chapters on IPF and interstitial lung disease. Dr. Maher qualified from Southampton Medical School, received his M.Sc. degree in Respiratory Medicine from Imperial College London, and earned his Ph.D. at University College London.« Less
- Paul W. Noble, M.D.
Dr. Noble serves as Professor and Chair of the Department of Medicine and Physician-in-Chief of Cedars-Sinai Medical Center, where he is also Director of the Women’s Guild Lung Institute and Vera and Paul Guerin Family Distinguished Chair in Pulmonary Medicine. More »
He was previously Chief of the Division of Pulmonary, Allergy and Critical Care Medicine at Duke University; Professor of Medicine at Yale University School of Medicine and Director of the Interstitial Lung Disease (ILD) Program at Yale-New Haven Hospital; and Assistant Professor at Johns Hopkins School of Medicine. Dr. Noble’s research focuses on elucidating the basic mechanisms of lung fibrosis and has been published in Science, Nature Medicine, The New England Journal of Medicine, The Journal of Experimental Medicine, and The Journal of Clinical Investigation. He has been involved in industry-sponsored clinical trials and served on steering committees for both the pirfenidone and nintedanib development programs that led to the first FDA-approved treatments for IPF in 2014. Dr. Noble continues to have an active clinical practice in ILD and has been selected by Best Doctors since 2007. He received his B.A. from Haverford College and his M.D. from New York University School of Medicine.« Less
- Arun J. Sanyal, M.D.
Dr. Sanyal is a Professor of Medicine, Physiology and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University Medical Center. More »
He also serves as Chairman of the NIH NASH Clinical Research Network, the NIMBLE consortium, and the Liver Forum for NASH and fibrosis. His research interests include all aspects of non-alcoholic fatty liver disease and NASH as well as complications of end-stage liver disease. He previously chaired the hepatobiliary pathophysiology study section of NIH, was a founding member of the Hepatology committee of the American Board of Internal Medicine, and has served as Secretary as well as President of the American Association for Study of Liver Diseases (AASLD). Dr. Sanyal has authored more than 350 articles in such publications as Cell Metabolism, Nature Medicine, New England Journal of Medicine, Lancet, Gastroenterology, Hepatology, and the Journal of Infectious Diseases and has been continuously funded by NIH since 1995. He received the Distinguished Mentorship Award from the American Gastroenterological Association and the Distinguished Scientific Achievement Award from the American Liver Foundation in 2017 and the Distinguished Achievement Award from AASLD in 2018.« Less